Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression

Clinical and Experimental Ophthalmology

Volumn 33, Issue 3, 2005, Pages 279-284

  Souza Filho, João Pessoa ^a,c   Martins, Maria C ^a,b   Caissie, Amanda L ^b   Torres, Virginia L L ^a   Fernandes, Luiza H C F ^b   Erwenne, Clelia M ^a   Burnier Jr , Miguel N ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

Chemotherapy; Histopathology; Immunohistochemistry; P glycoprotein; Retinoblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; CARBOPLATIN; ETOPOSIDE; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENUCLEATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; OPTIC NERVE; PRESCHOOL CHILD; PROTEIN EXPRESSION; RETINOBLASTOMA; TUMOR DIFFERENTIATION; BRACHYTHERAPY; ENZYME IMMUNOASSAY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETINA TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARBOPLATIN; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; NEOPLASM INVASIVENESS; P-GLYCOPROTEIN; RETINAL NEOPLASMS; RETINOBLASTOMA; VINCRISTINE;

EID: 23044511808     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2005.00991.x     Document Type: Article

References (20)

1. Deegan WF. Emerging strategies for the treatment of retinoblastoma. Curr Opin Ophthalmol 2003; 14: 291-5.
2. Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol 2003; 87: 1374-80.
3. Demirci H, Eagle RC, Shields CL, Shields JA. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 2003; 121: 1125-31.
4. Lumbroso L, Doz F, Urbieta M et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology 2002; 109: 1130-6.
5. Shields CL. Discussion: new retinoblastoma tumour formation in children initially treated with systemic carboplatin. Ophthalmology 2003; 110: 1994-5.
6. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
7. McNamara M, Clynes M, Dunne B et al. Multidrug resistance in ocular melanoma. Br J Ophthalmol 1996; 80: 1009-12.
8. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10: 159-65.
9. Dunne BM, McNamara M, Clynes M et al. MDR1 expression is associated with adverse survival in melanoma of uveal tract. Hum Pathol 1998; 29: 594-8.
10. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resitant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991; 98: 1425-31.
11. Gallie BL, Budning A, DeBoer G et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114: 1321-8.
12. Chan HSL, DeBoer G, Thorner PS, Haddad G, Gallie BL, Ling V. Multidrug resistance. Hematol Oncol Clin North Am 1994; 8: 383-410.
13. Chan HSL, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Eng J Med 1991; 325: 1608-14.
14. Chan HS, Lu Y, Grogan TM et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 1997; 57: 2325-30.
15. Khelfaoui F, Validire P, Auperin A et al. Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer 1996; 77: 1206-13.
16. Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998; 116: 887-93.
17. Ts'o MO, Zimmerman LE, Ellsworth RM. A cause of radioresistance in retinoblastoma: photoreceptor differentiation. Trans Am Acad Ophthalmol Otolaryngol 1970; 74: 959-69.
18. Schouten-van Meeteren AY, van der Valk P, van der Linden HC et al. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. Cancer 2001; 92: 2933-40.
19. Singh AD, Shields CL, Shields JA. Lack of response to chemoreduction in presumed well differentiated retinoblastoma. Pediatr Ophthalmol Strabismus 2002; 39: 107-9.
20. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-65.